Abstract
The great value of rifampicin as a suitable anti-tuberculous agent for intermittent therapy has been confirmed in several experimental and clinical studies. Unfortunately our actual knowledge of which size of doses should be chosen for rifampicin in the intermittent therapy after a preceding daily phase is still insufficient.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1976 Plenum Press, New York
About this chapter
Cite this chapter
Zierski, M., Bek, E., Marcinia, J., Szelagowicz, B. (1976). Re-Treatment of Chronic Pulmonary Tuberculosis with Low and High Dosages Rifampicin Regimens in the Continuation Intermittent Phase (A controlled comparison study). In: Williams, J.D., Geddes, A.M. (eds) Special Problems in Chemotherapy. Chemotherapy, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-3120-9_12
Download citation
DOI: https://doi.org/10.1007/978-1-4684-3120-9_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-3122-3
Online ISBN: 978-1-4684-3120-9
eBook Packages: Springer Book Archive